Improved Survival of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients with Undetectable HIV RNA

Oral Poster PresentationTuesday, 20 July 2010

Emma Page*, Eugenia Vispo, David E. Kaplan, Luciana Kikuchi, Marina Núñez, Mark Nelson, Pablo

Barreiro, Jorge Daruich, Kristen Marks, Rena Fox, Morris Sherman, Massimo Puoti, Norbert Bräu. Liver Cancer in HIV Study Group

* Chelsea & Westminster Hospital * Imperial College, London

HCC in HIV – HIV RNA Level and Survival: Methods• Retrospective• Inclusion Criteria: HIV+, HCV Ab, AASLD 2005

n=115

Undetectable: HIV RNA < 400 c/ml68 (59%)

51.463 (93%)

31949 (72%)Jul ’05

26 (40%)42 (62%)3 (4.4%)

Detectable: HIV RNA > 400 c/ml47 (41%)

51.543 (92%)

32036 (77%)May ’038 (18%)

21 (45%)7 (15%)

NageMaleCD4HCV

date Dxno ETOH

ScreeningCTP: C

HCC in HIV – HIV RNA Level and Survival Tumor Characteristics

HIV RNA <400n=68

HIV RNA 400+n=47

P

Hepatic Lesions: Single Tumor 52% 45% 0.52

Median Size Largest Tumor (cm), range 3.5 (0.5 – 18) 5.6 (2.0 – 20) 0.017

AFP Level, Median (ng/mL) 231 1,504 0.045

HCC Therapy  HIV RNA <400

n=68HIV RNA 400+

n=47P

Potentially Curative, n (%) Radiofrequency Ablation Percutaneous Ethanol Injection Surgical Resection Liver Transplantation

Effective, Non-Curative, n (%) Chemoembolization Sorafenib

No Therapy, n (%)

22 (32%)9382

23 (34%)203

23 (34%)

9 (19%)5400

10 (21%)91

28 (60%)

0.024

Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna

HCC in HIV – HIV RNA Level and Survival: Survival

All Patients

No HCC Therapy Effective, Non-Curative Therapy Potentially Curative Therapy

Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna

Thank you much for your kind attention

Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna